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Systemic sclerosis (SSc) is an idiopathic autoimmune con-
nective tissue disease which is characterised by vascular 
abnormalities, inflammation and fibrosis.1,2 The disease is 
likely initiated by a vascular injury, leading to inflamma-
tion and finally fibrosis. The fibrosis primarily affects the 
skin and can affect the lungs.3 The extent of skin thicken-
ing and organ involvement can delineate this disease into 
two subtypes: limited cutaneous SSc in which only limited 
to discrete areas of the skin and diffuse SSc in which there 
is larger involvement of the skin and internal organs. 
Currently, no treatment is licenced for the skin fibrotic ele-
ment of the disease, although recently treatments have 
been licenced for lung disease associated with SSc, such as 
nintedanib. Activation of quiescent fibroblasts to activated 
myofibroblasts that secrete copious amounts of extracel-
lular matrix is at the core of the disease, and understanding 
of how these cells are activated remains elusive.
Gremlin-1 is a bone morphogenetic protein (BMP) 
antagonist that is required for embryogenesis.4 Gremlin-1 
is part of the transforming growth factor (TGF)-β1 super-
family and acts to block by sequestering soluble BMPs. 
BMPs have to be tightly regulated, and thus, Gremlin-1 is 
one such protein that regulates this.4,5 Recently, Gremlin-1 
has been found to be associated with kidney,6,7 lung8,9 and 
skin fibrosis.10 We described very recently that overex-
pression of Gremlin-1 led to increased myofibroblast tran-
sition that was partially dependant on TGF-β1 signalling, 
as blockade of TGF-β1 mitigated fibrosis.11 Analysis of 
SSc fibroblasts compared to controls did not find elevated 




Introduction: Systemic sclerosis is an autoimmune connective tissue disease in which there is activation of the immune 
system, vascular disease and fibrosis. Activation of quiescent fibroblasts to myofibroblasts is key to disease pathogenesis. 
Gremlin-1 is a bone morphogenetic protein antagonist which is important in development and we recently reported in 
skin fibrosis. The aim of this study was to determine the serum circulating levels of Gremlin-1 in early diffuse systemic 
sclerosis.
Methods: Twenty-one early diffuse systemic sclerosis patients (less than 2 years from first non-Raynaud’s symptom) 
were included and age and sex-matched healthy controls. Serum was isolated from blood and measured with a specific 
enzyme-linked immunoassay for Gremlin-1. Clinical variables were also measured.
Results: Significantly elevated Gremlin-1 was found in sera of early diffuse systemic sclerosis patients (p < 0.001). In 
patients with interstitial lung disease, this compared to systemic sclerosis without evidence of interstitial lung disease, 
Gremlin-1 was significantly elevated (p < 0.0007). A correlation was found between circulating Gremlin-1 and modified 
Rodnan Skin Score, albeit weak.
Discussion: In early diffuse systemic sclerosis patients, elevated Gremlin-1 is found in serum. This is particularly 
prominent in systemic sclerosis–associated interstitial lung disease. This suggests that Gremlin-1 may be a biomarker for 
systemic sclerosis interstitial lung disease.
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levels of Gremlin-1. The aim of this study is to determine 
the levels of Gremlin-1 in the sera of SSc patients with 
early diffuse SSc disease.
Methods
Twenty-one patients with early diffuse SSc were 
involved in the study; this is a retrospective study in a 
single-centre study. Patients were defined as early dif-
fuse SSc defined as <2 years since the first non-
Raynaud’s symptom. All patients fulfilled the American 
College of Rhuematology (ACR) criteria for a diagnosis 
of diffuse SSc and full informed consent was provided. 
The study has full ethical approval with the local research 
ethics committee (REC) with approval no. REC/13/
NE/0089 and followed the declaration of Helsinki guide-
lines. Healthy controls (HCs) were age and gender 
matched (n = 20). 15 mL blood was drawn from each 
donor arm, and serum was isolated by centrifugation at 
2000g for 15 min.
ELISA
A commercially available enzyme-linked immunosorbent 
assay (ELISA) was used purchased from Reagent Genie 
(Dublin, Republic of Ireland). This recognises human 
Gremlin-1. A standard curve was constructed from known 
amounts of Gremlin-1, and data were calculated from 
this curve.
Data were tested for normality using the Kolmogorov–
Smirnov test of normality. Normal distribution as deter-
mined by the Kolmogorov–Smirnov test, Student’s t-test 
was undertaken. Student’s t-test was used to test differ-
ences between HC and SSc patients with a p-value < 
0.05 considered statistically significant. The Mann–
Whitney U test was used to compare differences between 
SSc without lung disease and those with. For correlation 
analysis, Pearson’s correlation r value was calculated 
using Prism™ software package.
Results
Twenty-one early diffuse SSc patients were included in 
this study with 20 HCs. Table 1 gives the patients’ 
demographics. Of the SSc patients, 5 had interstitial 
lung disease (ILD) and 16 did not have any evidence 
of ILD. Diffusing capacity of the lung for carbon mon-
oxide (DLCO)% predicted of 60% or less was used to 
define ILD. No patient was receiving any treatment 
medications.
Gremlin-1 levels in SSc were significantly higher com-
pared to HCs (Figure 1): mean = 1.14 ng/mL (standard 
deviation (SD) = 0.7) versus mean = 14.32 ng/mL (SD = 
5.1), n = 21, p < 0.0001; Student’s t-test.
Patients with SSc-associated ILD5 compared to SSc 
patients without ILD12 had significantly elevated serum 
Gremlin-1 levels (p = 0.0007; Mann–Whitney U test; 
Figure 2).
Table 1. SSc diffuse patient demographics.
Patient number Age (years) Sex Autoantibodies mRSS (1) Treatment ILD DLCO%
Patient_1 48 F Scl-70  9 None N 85
Patient_2 54 F Scl-70 16 None N 82
Patient_3 51 F RNA-polIII 10 None N 89
Patient_4 66 F Scl-70 16 None Y 60
Patient_5 39 F Scl-70 11 None N 73
Patient_6 52 F Scl-70 12 None N 79
Patient_7 41 M Scl-70 10 None N 87
Patient_8 49 F Scl-70 14 None Y 57
Patient_9 55 F RNA-polIII 17 None Y 52
Patient_10 42 F Scl-70 21 None N 91
Patient_11 57 M Scl-70 14 None N 75
Patient_12 35 F Scl-70 19 None N 82
Patient_13 47 F Scl-70 11 None N 76
Patient_14 61 F Scl-70 15 None N 74
Patient_15 55 F Scl-70 21 None Y 50
Patient_16 37 F Scl-70 18 None N 78
Patient_17 48 F Scl-70 22 None Y 52
Patient_18 51 F Scl-70 16 None N 77
Patient_19 39 F RNA-polIII 12 None N 93
Patient_20 42 F Scl-70 26 None N 70
Patient_21 37 M Scl-70 19 None N 74
ILD: interstitial lung disease; DLCO: carbon monoxide lung diffusion capacity % predicted.
1 mRSS  is the modified Rodnan Skin Score based on 1–51.
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We next sought to ascertain if there is a correlation 
between sera Gremlin-1 levels and skin thickness using the 
modified Rodnan Skin Score (mRSS); a weak negative 
correlation was found between Gremlin-1 amounts and 
mRSS (r = −0.466; p = 0.033, n = 21) (see Figure 3). 
This suggests a weak inverse correlation.
Discussion
We have recently described a pro-fibrotic role of Gremlin-1 
in dermal fibrosis in SSc. The aim of this study was to 
assess the circulating levels of Gremlin-1 in early diffuse 
SSc. We identified significantly elevated levels of 
Gremlin-1 compared to HCs. Furthermore, we also dem-
onstrated significantly elevated levels of Gremlin-1 in 
SSc-associated ILD compared to patients without ILD.
Gremlin-1 is a BMP antagonist that regulates BMP sig-
nalling, but it is associated with certain tumours13 includ-
ing breast cancer,14 and fibrosis of the kidney, lungs9 and 
we recently described the skin as a target cell type. 
Overexpression of Gremlin-1 led to a significant increase 
in Extra cellular matrix (ECM) and cell migration; how-
ever, we did not see elevated levels of Gremlin-1 in the 
fibroblasts. This study sought to identify is SSc early dif-
fuse patients had elevated Gremlin-1 levels. We found 
among the 21 SSc patients elevated Gremlin-1, and in the 
patients subdivided into those with ILD5 and those with-
out,12 we could see significantly elevated levels of 
Gremlin-1. This is suggestive of a biomarker for ILD dis-
ease associated with SSc.
Given that SSc-associated ILD is responsible for the 
high mortality associated with the disease,15 this could be 
of possible clinical utility to differentiate patients. Tissue 
Gremlin-1 has been associated with IPF,8 and in IPF cell, 
Gremlin-1 has been found to be fibrotic and regulated by 
microRNA27b.16 Furthermore, overexpression of 
Gremlin-1 in rat lungs by adenoviral vector results in lung 
fibrosis.12 Interestingly, in sarcoidosis, the associated 
development of fibrosis in these patients was associated 
with a specific polymorphism in Gremlin-1 gene.17 Most 
recently, although serum levels of Gremlin-1 have been 
found to be significantly elevated compared to controls and 
also patients with idiopathic interstitial pneumonia also had 
higher serum Gremlin-1 levels.18 This all suggests that 
Figure 1. Elevated Gremlin-1 in SSc patients. Gremlin-1 was 
quantified by specific ELISA. Data are each individual point 
represent a single donor.
***p < 0.0001 (Student’s t-test).
Figure 2. Elevated Gremlin-1 in SSc patients subdivided with 
those who have and have not ILD. Data are individual points 
for each donor.
***p = 0.007 (Mann–Whitney U test).
Figure 3. Correlation between Gremlin-1 and mRSS skin 
score. Negative correlation between mRSS and serum 
Gremlin-1.
p = 0.033; r = −0.466; n = 21 donors.
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Gremlin-1 could be used a clinical biomarker. We particu-
larly focused on early diffuse SSc patients as we had previ-
ously found an induction with IL-6 trans signalling10 and 
with IL-6 being such an important molecule in early dis-
ease19 we focussed on this. It is now accepted that interven-
tions in early disease are the best possible way to modify 
disease course.20 Interestingly, Gremlin-1 has also been 
found to be critically involved in hereditary pulmonary 
hypertension in mice and patients with hereditary pulmo-
nary hypertension.21 It is possible that there is an interrela-
tionship between IL-6 and Gremlin-1 levels. Given that 
IL-6 appears to regulate Gremlin-1 in vitro,10 it maybe that 
high IL-6 serum correlates with Gremlin-1 levels, although 
in this study we did not measure IL-6. The patients were 
early diffuse and thus likely to be much more ‘inflamma-
tory’ subsets so one would predict high IL-6 levels.
We also analysed a possible association with skin thick-
ness (by mRSS) and serum Gremlin-1 levels and found a 
weak negative correlation (r = −0.466). This is a relatively 
weak correlation, and the modesty likely reflects the num-
ber of patients. The biological relevance of this, if any, 
remains unclear to the authors. In summary, we demon-
strate elevated levels of the pro-fibrotic morphogen 
Gremlin-1 and that this is particularly marked in SSc 
patients with ILD. Whether Gremlin-1 can predict disease 
progression is currently unknown and we did not perform 
a prospective study. This should be examined in prospec-
tive follow-up studies to determine if it can predict dis-
ease. We recently demonstrated that inhibition of 
Gremlin-1 with small interfering RNA in fibroblasts 
retarded collagen deposition,11 suggesting that Gremlin-1 
is a therapeutic target in this disease.
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